Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CervoMed Inc.CRVO · Entity 7338 | Director · 10% owner | June 11, 2026 | June 15, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CervoMed Inc.
Report date June 11, 2026 · Filed June 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Trusts | 1,795,865 |
Reported balance
After 2026-06-11 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2026-06-11 · Purchase · Acquired 955,414 · Balance 1,795,865 F1: On June 11, 2026, the Issuer completed a private placement (the "Private Placement") pursuant to a securities purchase agreement, dated June 9, 2026 (the "Purchase Agreement"), with the Joshua S. Boger 2021 Trust DTD 12/09/2021, of which the Reporting Person serves as the sole trustee (the "JSB 2021 Trust"), and certain accredited investors named therein. Pursuant to the Purchase Agreement, the JSB 2021 Trust purchased an aggregate of 955,414 units (the "Units"), each Unit comprised of (i) one share of the Issuer's common stock, par value $0.001 per share (the "Common Stock"), (ii) one Series B warrant to purchase one share of Common Stock or a pre-funded warrant to purchase one share of Common Stock (each, a "Series B Warrant"), and (iii) one Series C warrant to purchase one share of Common Stock or a pre-funded warrant to purchase one share of Common Stock (each, a "Series C Warrant") for a purchase price of $3.14 per Unit. F2: After giving effect to all transactions described herein, consists of (i) 1,600,117 shares of the Issuer's common stock held by the JSB 2021 Trust and (ii) 195,748 shares of the Issuer's common stock held by The Amy S. Boger 2021 Trust (the "ASB 2021 Trust"). The Reporting Person serves as the sole trustee of each of the JSB 2021 Trust and the ASB 2021 Trust. The Reporting Person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose. |
| Series B WarrantsSEC Table II · derivative / convertible security · Conversion / exercise price $3.32 · Expires 2031-06-11 | IndirectBy Trust | 955,414 |
Reported balance
After 2026-06-11 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-06-11 · Purchase · Acquired 955,414 · Balance 955,414 F3: The Series B Warrants have an exercise price equal to $3.32 per share of Common Stock or $3.319 per pre-funded warrant, are exercisable immediately, and will expire five years from the issuance date of the Series B Warrant. F5: Under the terms of the Series B Warrants and the Series C Warrants, the Issuer may not effect the exercise of any portion thereof, and the JSB 2021 Trust will not have the right to exercise any portion thereof, which, upon giving effect to such exercise, would cause the JSB 2021 Trust (together with its affiliates) to own more than 19.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise. To the extent that exercise of the Series B Warrants or Series C Warrants will result in the JSB 2021 Trust (together with its affiliates) beneficially owning shares of Common Stock above such ownership limitations, the JSB 2021 Trust may exercise its Series B Warrants or Series C Warrants for pre-funded warrants to purchase shares of Common Stock, which pre-funded warrants will include a substantially similar maximum ownership limitation. F1: On June 11, 2026, the Issuer completed a private placement (the "Private Placement") pursuant to a securities purchase agreement, dated June 9, 2026 (the "Purchase Agreement"), with the Joshua S. Boger 2021 Trust DTD 12/09/2021, of which the Reporting Person serves as the sole trustee (the "JSB 2021 Trust"), and certain accredited investors named therein. Pursuant to the Purchase Agreement, the JSB 2021 Trust purchased an aggregate of 955,414 units (the "Units"), each Unit comprised of (i) one share of the Issuer's common stock, par value $0.001 per share (the "Common Stock"), (ii) one Series B warrant to purchase one share of Common Stock or a pre-funded warrant to purchase one share of Common Stock (each, a "Series B Warrant"), and (iii) one Series C warrant to purchase one share of Common Stock or a pre-funded warrant to purchase one share of Common Stock (each, a "Series C Warrant") for a purchase price of $3.14 per Unit. F6: The Series B Warrants and Series C Warrants are owned by the JSB 2021 Trust. |
| Series C WarrantsSEC Table II · derivative / convertible security · Conversion / exercise price $3.14 · Expires 2027-06-11 | IndirectBy Trust | 955,414 |
Reported balance
After 2026-06-11 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-06-11 · Purchase · Acquired 955,414 · Balance 955,414 F4: The Series C Warrants have an exercise price equal to $3.14 per share of Common Stock or $3.139 per pre-funded warrant, are exercisable immediately, and will expire one year from the issuance date of the Series C Warrant. F5: Under the terms of the Series B Warrants and the Series C Warrants, the Issuer may not effect the exercise of any portion thereof, and the JSB 2021 Trust will not have the right to exercise any portion thereof, which, upon giving effect to such exercise, would cause the JSB 2021 Trust (together with its affiliates) to own more than 19.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise. To the extent that exercise of the Series B Warrants or Series C Warrants will result in the JSB 2021 Trust (together with its affiliates) beneficially owning shares of Common Stock above such ownership limitations, the JSB 2021 Trust may exercise its Series B Warrants or Series C Warrants for pre-funded warrants to purchase shares of Common Stock, which pre-funded warrants will include a substantially similar maximum ownership limitation. F1: On June 11, 2026, the Issuer completed a private placement (the "Private Placement") pursuant to a securities purchase agreement, dated June 9, 2026 (the "Purchase Agreement"), with the Joshua S. Boger 2021 Trust DTD 12/09/2021, of which the Reporting Person serves as the sole trustee (the "JSB 2021 Trust"), and certain accredited investors named therein. Pursuant to the Purchase Agreement, the JSB 2021 Trust purchased an aggregate of 955,414 units (the "Units"), each Unit comprised of (i) one share of the Issuer's common stock, par value $0.001 per share (the "Common Stock"), (ii) one Series B warrant to purchase one share of Common Stock or a pre-funded warrant to purchase one share of Common Stock (each, a "Series B Warrant"), and (iii) one Series C warrant to purchase one share of Common Stock or a pre-funded warrant to purchase one share of Common Stock (each, a "Series C Warrant") for a purchase price of $3.14 per Unit. F6: The Series B Warrants and Series C Warrants are owned by the JSB 2021 Trust. |
| Common StockSEC Table I · non-derivative | Direct | 216,817 |
Reported balance
Holding disclosure · report date 2026-06-11 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 216,817 |
Filing footnotes · ownership attribution and instrument terms
F1: On June 11, 2026, the Issuer completed a private placement (the "Private Placement") pursuant to a securities purchase agreement, dated June 9, 2026 (the "Purchase Agreement"), with the Joshua S. Boger 2021 Trust DTD 12/09/2021, of which the Reporting Person serves as the sole trustee (the "JSB 2021 Trust"), and certain accredited investors named therein. Pursuant to the Purchase Agreement, the JSB 2021 Trust purchased an aggregate of 955,414 units (the "Units"), each Unit comprised of (i) one share of the Issuer's common stock, par value $0.001 per share (the "Common Stock"), (ii) one Series B warrant to purchase one share of Common Stock or a pre-funded warrant to purchase one share of Common Stock (each, a "Series B Warrant"), and (iii) one Series C warrant to purchase one share of Common Stock or a pre-funded warrant to purchase one share of Common Stock (each, a "Series C Warrant") for a purchase price of $3.14 per Unit.
F2: After giving effect to all transactions described herein, consists of (i) 1,600,117 shares of the Issuer's common stock held by the JSB 2021 Trust and (ii) 195,748 shares of the Issuer's common stock held by The Amy S. Boger 2021 Trust (the "ASB 2021 Trust"). The Reporting Person serves as the sole trustee of each of the JSB 2021 Trust and the ASB 2021 Trust. The Reporting Person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.
F3: The Series B Warrants have an exercise price equal to $3.32 per share of Common Stock or $3.319 per pre-funded warrant, are exercisable immediately, and will expire five years from the issuance date of the Series B Warrant.
F4: The Series C Warrants have an exercise price equal to $3.14 per share of Common Stock or $3.139 per pre-funded warrant, are exercisable immediately, and will expire one year from the issuance date of the Series C Warrant.
F5: Under the terms of the Series B Warrants and the Series C Warrants, the Issuer may not effect the exercise of any portion thereof, and the JSB 2021 Trust will not have the right to exercise any portion thereof, which, upon giving effect to such exercise, would cause the JSB 2021 Trust (together with its affiliates) to own more than 19.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise. To the extent that exercise of the Series B Warrants or Series C Warrants will result in the JSB 2021 Trust (together with its affiliates) beneficially owning shares of Common Stock above such ownership limitations, the JSB 2021 Trust may exercise its Series B Warrants or Series C Warrants for pre-funded warrants to purchase shares of Common Stock, which pre-funded warrants will include a substantially similar maximum ownership limitation.
F6: The Series B Warrants and Series C Warrants are owned by the JSB 2021 Trust.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
VERTEX PHARMACEUTICALS INC / MA
Report date June 08, 2017 · Filed June 09, 2017
Section 16 reporting ended · disclosed 2017-06-09. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 284,088 |
Reported balance
After 2017-06-08 transaction · row 1
1 source rowRow 1 · 2017-06-08 · Exercise / conversion · Acquired 2,941 · Balance 284,088 F1: Each deferred stock unit represents one share of common stock and converted into common stock upon the termination of Dr. Boger's service on our board of directors on 06/08/2017. |
| Deferred Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2017-06-08 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2017-06-08 · Exercise / conversion · Disposed 2,941 · Balance 0 F1: Each deferred stock unit represents one share of common stock and converted into common stock upon the termination of Dr. Boger's service on our board of directors on 06/08/2017. |
| Common StockSEC Table I · non-derivative | Indirect401(k) | 13,286 |
Reported balance
Holding disclosure · report date 2017-06-08 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 13,286 |
| Common StockSEC Table I · non-derivative | IndirectCommon Stock Held In Trust | 64,525 |
Reported balance
Holding disclosure · report date 2017-06-08 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 64,525 |
Filing footnotes · ownership attribution and instrument terms
F1: Each deferred stock unit represents one share of common stock and converted into common stock upon the termination of Dr. Boger's service on our board of directors on 06/08/2017.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 13, 2008 Filed Aug 14, 2008 18:36 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 12,400 | $10.19 | $126,356.00 |
DisclosureSEC source: 0000875320-08-000065 · edgar.xml · nonDerivative · entry 1 BOGER JOSHUA S · CIK 0001197023 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,107,444 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 06, 2008 Filed Aug 7, 2008 16:41 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Options · Derivative | 12,400 | $0.00 Strike: $10.19 | $0.00 |
DisclosureSEC source: 0000875320-08-000063 · edgar.xml · derivative · entry 6 BOGER JOSHUA S · CIK 0001197023 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,378 Underlying: Common Stock · 12,400 shares Expires 2008-09-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: Fully vested. Read SEC document |
| August 06, 2008 Filed Aug 7, 2008 16:41 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 6,600 | $31.24 | $206,184.00 |
DisclosureSEC source: 0000875320-08-000063 · edgar.xml · nonDerivative · entry 3 BOGER JOSHUA S · CIK 0001197023 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,095,044 F1 · kind: Transaction for sales of common stock made pursuant to Dr. Boger's company approved trading plan established under Rule 10b5-1. F3 · price: Open market sales reported on this line occurred at a weighted average price of $31.24 (range $31.00 to $31.91). F4 · price: Dr. Boger undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| August 06, 2008 Filed Aug 7, 2008 16:41 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 5,800 | $30.62 | $177,596.00 |
DisclosureSEC source: 0000875320-08-000063 · edgar.xml · nonDerivative · entry 2 BOGER JOSHUA S · CIK 0001197023 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,101,644 F1 · kind: Transaction for sales of common stock made pursuant to Dr. Boger's company approved trading plan established under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $30.62 (range $30.30 to $30.99). F4 · price: Dr. Boger undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| August 06, 2008 Filed Aug 7, 2008 16:41 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 12,400 | $10.19 | $126,356.00 |
DisclosureSEC source: 0000875320-08-000063 · edgar.xml · nonDerivative · entry 1 BOGER JOSHUA S · CIK 0001197023 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,107,444 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 30, 2008 Filed Jul 31, 2008 19:16 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Options · Derivative | 12,400 | $0.00 Strike: $10.19 | $0.00 |
DisclosureSEC source: 0000875320-08-000062 · edgar.xml · derivative · entry 6 BOGER JOSHUA S · CIK 0001197023 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,778 Underlying: Common Stock · 12,400 shares Expires 2008-09-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: Fully vested. Read SEC document |
| July 30, 2008 Filed Jul 31, 2008 19:16 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 9,816 | $32.91 | $323,044.56 |
DisclosureSEC source: 0000875320-08-000062 · edgar.xml · nonDerivative · entry 3 BOGER JOSHUA S · CIK 0001197023 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,778 F1 · kind: Transaction for sales of common stock made pursuant to Dr. Boger's company approved trading plan established under Rule 10b5-1. F3 · price: Open market sales reported on this line occurred at a weighted average price of $32.91 (range $32.59 to $33.25). F4 · price: Dr. Boger undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| July 30, 2008 Filed Jul 31, 2008 19:16 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 2,584 | $32.38 | $83,669.92 |
DisclosureSEC source: 0000875320-08-000062 · edgar.xml · nonDerivative · entry 2 BOGER JOSHUA S · CIK 0001197023 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,594 F1 · kind: Transaction for sales of common stock made pursuant to Dr. Boger's company approved trading plan established under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $32.38 (range $31.58 to $32.57). F4 · price: Dr. Boger undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| July 30, 2008 Filed Jul 31, 2008 19:16 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 12,400 | $10.19 | $126,356.00 |
DisclosureSEC source: 0000875320-08-000062 · edgar.xml · nonDerivative · entry 1 BOGER JOSHUA S · CIK 0001197023 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,178 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 30, 2008 Filed Aug 7, 2008 16:47 UTC Amendment | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 9,816 | $32.91 | $323,044.56 |
DisclosureSEC source: 0000875320-08-000064 · edgar.xml · nonDerivative · entry 3 BOGER JOSHUA S · CIK 0001197023 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,095,044 F1 · kind: Transaction for sales of common stock made pursuant to Dr. Boger's company approved trading plan established under Rule 10b5-1. F3 · price: Open market sales reported on this line occurred at a weighted average price of $32.91 (range $32.59 to $33.25). F4 · price: Dr. Boger undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · balance_after: Amount of securities beneficially owned following reported transaction was incorrect in original filing. Read SEC document |
| July 30, 2008 Filed Aug 7, 2008 16:47 UTC Amendment | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 2,584 | $32.38 | $83,669.92 |
DisclosureSEC source: 0000875320-08-000064 · edgar.xml · nonDerivative · entry 2 BOGER JOSHUA S · CIK 0001197023 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,104,860 F1 · kind: Transaction for sales of common stock made pursuant to Dr. Boger's company approved trading plan established under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $32.38 (range $31.58 to $32.57). F4 · price: Dr. Boger undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · balance_after: Amount of securities beneficially owned following reported transaction was incorrect in original filing. Read SEC document |
| July 30, 2008 Filed Aug 7, 2008 16:47 UTC Amendment | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 12,400 | $10.19 | $126,356.00 |
DisclosureSEC source: 0000875320-08-000064 · edgar.xml · nonDerivative · entry 1 BOGER JOSHUA S · CIK 0001197023 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,107,444 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · balance_after: Amount of securities beneficially owned following reported transaction was incorrect in original filing. Read SEC document |
| July 24, 2008 Filed Jul 25, 2008 15:01 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Options · Derivative | 118,000 | $0.00 Strike: $32.16 | $0.00 |
DisclosureSEC source: 0000875320-08-000054 · edgar.xml · derivative · entry 1 BOGER JOSHUA S · CIK 0001197023 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,000 Underlying: Common Stock · 118,000 shares Expires 2018-07-23 F1 · derivative.exercise_date: Right to buy under 2006 Stock and Option Plan, vesting in 16 equal quarterly installments from 07/24/2008. Read SEC document |
| June 27, 2008 Filed Jun 30, 2008 18:56 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GiftCommon Stock | 45,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000875320-08-000047 · edgar.xml · nonDerivative · entry 1 BOGER JOSHUA S · CIK 0001197023 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,095,044 F1 · shares: Common stock gifted to a variety of non-profit entities. Read SEC document |
| February 12, 2008 Filed Feb 14, 2008 17:01 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option · Derivative | 7,912 | $0.00 Strike: $15.60 | $0.00 |
DisclosureSEC source: 0000875320-08-000014 · edgar.xml · derivative · entry 6 BOGER JOSHUA S · CIK 0001197023 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,912 shares Expires 2013-01-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested. Read SEC document |
| February 12, 2008 Filed Feb 14, 2008 17:01 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option · Derivative | 4,823 | $0.00 Strike: $15.87 | $0.00 |
DisclosureSEC source: 0000875320-08-000014 · edgar.xml · derivative · entry 5 BOGER JOSHUA S · CIK 0001197023 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,823 shares Expires 2012-07-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested. Read SEC document |
| February 12, 2008 Filed Feb 14, 2008 17:01 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 7,912 | $15.60 | $123,427.20 |
DisclosureSEC source: 0000875320-08-000014 · edgar.xml · nonDerivative · entry 2 BOGER JOSHUA S · CIK 0001197023 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,140,044 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 12, 2008 Filed Feb 14, 2008 17:01 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 4,823 | $15.87 | $76,541.01 |
DisclosureSEC source: 0000875320-08-000014 · edgar.xml · nonDerivative · entry 1 BOGER JOSHUA S · CIK 0001197023 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,132,132 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 07, 2008 Filed Feb 11, 2008 20:49 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option · Derivative | 118,000 | $0.00 Strike: $18.93 | $0.00 |
DisclosureSEC source: 0000875320-08-000005 · edgar.xml · derivative · entry 4 BOGER JOSHUA S · CIK 0001197023 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,000 Underlying: Common Stock · 118,000 shares Expires 2018-02-06 F3 · derivative.exercise_date: Right to buy under 2006 Stock and Option Plan, vesting in 16 equal quarterly installments from 02/07/2008, subject to shareholder approval. Read SEC document |
| February 07, 2008 Filed Feb 11, 2008 20:49 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 31,467 | $0.01 | $314.67 |
DisclosureSEC source: 0000875320-08-000005 · edgar.xml · nonDerivative · entry 1 BOGER JOSHUA S · CIK 0001197023 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,127,309 F1 · shares: Stock grant made under 2006 Stock and Option Plan, vesting on 2/7/2012, subject to acceleration upon achievement of certain performance-based milestones. Read SEC document |
| December 07, 2007 Filed Dec 10, 2007 17:16 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option · Derivative | 17,686 | $0.00 Strike: $13.67 | $0.00 |
DisclosureSEC source: 0000875320-07-000120 · edgar.xml · derivative · entry 11 BOGER JOSHUA S · CIK 0001197023 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,686 shares Expires 2007-12-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: Fully vested. Read SEC document |
| December 07, 2007 Filed Dec 10, 2007 17:16 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 800 | $25.34 | $20,272.00 |
DisclosureSEC source: 0000875320-07-000120 · edgar.xml · nonDerivative · entry 8 BOGER JOSHUA S · CIK 0001197023 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,095,842 F1 · kind: Transaction for sales of common stock made pursuant to Dr. Boger's company approved trading plan established under Rule 10b5-1. F8 · kind: Aggregate sales made at prices between $25.25 and $25.39. Read SEC document |
| December 07, 2007 Filed Dec 10, 2007 17:16 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 2,186 | $25.45 | $55,633.70 |
DisclosureSEC source: 0000875320-07-000120 · edgar.xml · nonDerivative · entry 7 BOGER JOSHUA S · CIK 0001197023 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,096,642 F1 · kind: Transaction for sales of common stock made pursuant to Dr. Boger's company approved trading plan established under Rule 10b5-1. F7 · kind: Aggregate sales made at prices between $25.40 and $25.49. Read SEC document |
| December 07, 2007 Filed Dec 10, 2007 17:16 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 2,200 | $25.55 | $56,210.00 |
DisclosureSEC source: 0000875320-07-000120 · edgar.xml · nonDerivative · entry 6 BOGER JOSHUA S · CIK 0001197023 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,098,828 F1 · kind: Transaction for sales of common stock made pursuant to Dr. Boger's company approved trading plan established under Rule 10b5-1. F6 · kind: Aggregate sales made at prices between $25.50 and $25.59. Read SEC document |
| December 07, 2007 Filed Dec 10, 2007 17:16 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 6,600 | $25.64 | $169,224.00 |
DisclosureSEC source: 0000875320-07-000120 · edgar.xml · nonDerivative · entry 5 BOGER JOSHUA S · CIK 0001197023 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,101,028 F1 · kind: Transaction for sales of common stock made pursuant to Dr. Boger's company approved trading plan established under Rule 10b5-1. F5 · kind: Aggregate sales made at prices between $25.60 and $25.69. Read SEC document |
| December 07, 2007 Filed Dec 10, 2007 17:16 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 3,400 | $25.74 | $87,516.00 |
DisclosureSEC source: 0000875320-07-000120 · edgar.xml · nonDerivative · entry 4 BOGER JOSHUA S · CIK 0001197023 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,107,628 F1 · kind: Transaction for sales of common stock made pursuant to Dr. Boger's company approved trading plan established under Rule 10b5-1. F4 · kind: Aggregate sales made at prices between $25.70 and $25.79. Read SEC document |
| December 07, 2007 Filed Dec 10, 2007 17:16 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,900 | $25.85 | $49,115.00 |
DisclosureSEC source: 0000875320-07-000120 · edgar.xml · nonDerivative · entry 3 BOGER JOSHUA S · CIK 0001197023 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,111,028 F1 · kind: Transaction for sales of common stock made pursuant to Dr. Boger's company approved trading plan established under Rule 10b5-1. F3 · kind: Aggregate sales made at prices between $25.81 and $25.89. Read SEC document |
| December 07, 2007 Filed Dec 10, 2007 17:16 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 600 | $25.95 | $15,570.00 |
DisclosureSEC source: 0000875320-07-000120 · edgar.xml · nonDerivative · entry 2 BOGER JOSHUA S · CIK 0001197023 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,112,928 F1 · kind: Transaction for sales of common stock made pursuant to Dr. Boger's company approved trading plan established under Rule 10b5-1. F2 · kind: Aggregate sales made at prices between $25.91 and $26.02. Read SEC document |
| December 07, 2007 Filed Dec 10, 2007 17:16 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 17,686 | $13.67 | $241,767.62 |
DisclosureSEC source: 0000875320-07-000120 · edgar.xml · nonDerivative · entry 1 BOGER JOSHUA S · CIK 0001197023 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,113,528 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 06, 2007 Filed Dec 7, 2007 20:06 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option · Derivative | 17,500 | $0.00 Strike: $13.67 | $0.00 |
DisclosureSEC source: 0000875320-07-000119 · edgar.xml · derivative · entry 14 BOGER JOSHUA S · CIK 0001197023 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,686 Underlying: Common Stock · 17,500 shares Expires 2007-12-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F12 · derivative.exercise_date: Fully vested. Read SEC document |
| December 06, 2007 Filed Dec 7, 2007 20:06 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,200 | $25.14 | $30,168.00 |
DisclosureSEC source: 0000875320-07-000119 · edgar.xml · nonDerivative · entry 11 BOGER JOSHUA S · CIK 0001197023 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,095,842 F1 · kind: Transaction for sales of common stock made pursuant to Dr. Boger's company approved trading plan established under Rule 10b5-1. F11 · kind: Aggregate sales made at prices between $25.10 and $25.19. Read SEC document |
| December 06, 2007 Filed Dec 7, 2007 20:06 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 800 | $25.27 | $20,216.00 |
DisclosureSEC source: 0000875320-07-000119 · edgar.xml · nonDerivative · entry 10 BOGER JOSHUA S · CIK 0001197023 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,097,042 F1 · kind: Transaction for sales of common stock made pursuant to Dr. Boger's company approved trading plan established under Rule 10b5-1. F10 · kind: Aggregate sales made at prices between $25.22 and $25.29. Read SEC document |
| December 06, 2007 Filed Dec 7, 2007 20:06 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 900 | $25.34 | $22,806.00 |
DisclosureSEC source: 0000875320-07-000119 · edgar.xml · nonDerivative · entry 9 BOGER JOSHUA S · CIK 0001197023 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,097,842 F1 · kind: Transaction for sales of common stock made pursuant to Dr. Boger's company approved trading plan established under Rule 10b5-1. F9 · kind: Aggregate sales made at prices between $25.31 and $25.39. Read SEC document |
| December 06, 2007 Filed Dec 7, 2007 20:06 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 4,400 | $25.47 | $112,068.00 |
DisclosureSEC source: 0000875320-07-000119 · edgar.xml · nonDerivative · entry 8 BOGER JOSHUA S · CIK 0001197023 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,098,742 F1 · kind: Transaction for sales of common stock made pursuant to Dr. Boger's company approved trading plan established under Rule 10b5-1. F8 · kind: Aggregate sales made at prices between $25.40 and $25.49. Read SEC document |
| December 06, 2007 Filed Dec 7, 2007 20:06 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 2,800 | $25.53 | $71,484.00 |
DisclosureSEC source: 0000875320-07-000119 · edgar.xml · nonDerivative · entry 7 BOGER JOSHUA S · CIK 0001197023 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,103,142 F1 · kind: Transaction for sales of common stock made pursuant to Dr. Boger's company approved trading plan established under Rule 10b5-1. F7 · kind: Aggregate sales made at prices between $25.50 and $25.58. Read SEC document |
| December 06, 2007 Filed Dec 7, 2007 20:06 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 2,500 | $25.63 | $64,075.00 |
DisclosureSEC source: 0000875320-07-000119 · edgar.xml · nonDerivative · entry 6 BOGER JOSHUA S · CIK 0001197023 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,105,942 F1 · kind: Transaction for sales of common stock made pursuant to Dr. Boger's company approved trading plan established under Rule 10b5-1. F6 · kind: Aggregate sales made at prices between $25.60 and $25.67. Read SEC document |
| December 06, 2007 Filed Dec 7, 2007 20:06 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,300 | $25.75 | $33,475.00 |
DisclosureSEC source: 0000875320-07-000119 · edgar.xml · nonDerivative · entry 5 BOGER JOSHUA S · CIK 0001197023 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,108,442 F1 · kind: Transaction for sales of common stock made pursuant to Dr. Boger's company approved trading plan established under Rule 10b5-1. F5 · kind: Aggregate sales made at prices between $25.71 and $25.79. Read SEC document |
| December 06, 2007 Filed Dec 7, 2007 20:06 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,000 | $25.84 | $25,840.00 |
DisclosureSEC source: 0000875320-07-000119 · edgar.xml · nonDerivative · entry 4 BOGER JOSHUA S · CIK 0001197023 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,109,742 F1 · kind: Transaction for sales of common stock made pursuant to Dr. Boger's company approved trading plan established under Rule 10b5-1. F4 · kind: Aggregate sales made at prices between $25.81 and $25.89. Read SEC document |
| December 06, 2007 Filed Dec 7, 2007 20:06 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,900 | $25.95 | $49,305.00 |
DisclosureSEC source: 0000875320-07-000119 · edgar.xml · nonDerivative · entry 3 BOGER JOSHUA S · CIK 0001197023 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,110,742 F1 · kind: Transaction for sales of common stock made pursuant to Dr. Boger's company approved trading plan established under Rule 10b5-1. F3 · kind: Aggregate sales made at prices between $25.90 and $25.99. Read SEC document |
| December 06, 2007 Filed Dec 7, 2007 20:06 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 700 | $26.01 | $18,207.00 |
DisclosureSEC source: 0000875320-07-000119 · edgar.xml · nonDerivative · entry 2 BOGER JOSHUA S · CIK 0001197023 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,112,642 F1 · kind: Transaction for sales of common stock made pursuant to Dr. Boger's company approved trading plan established under Rule 10b5-1. F2 · kind: Aggregate sales made at prices between $26.00 and $26.05. Read SEC document |
| December 06, 2007 Filed Dec 7, 2007 20:06 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 17,500 | $13.67 | $239,225.00 |
DisclosureSEC source: 0000875320-07-000119 · edgar.xml · nonDerivative · entry 1 BOGER JOSHUA S · CIK 0001197023 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,113,342 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 04, 2007 Filed Dec 5, 2007 17:21 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option · Derivative | 17,500 | $0.00 Strike: $13.67 | $0.00 |
DisclosureSEC source: 0000875320-07-000118 · edgar.xml · derivative · entry 9 BOGER JOSHUA S · CIK 0001197023 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,186 Underlying: Common Stock · 17,500 shares Expires 2007-12-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: Fully vested. Read SEC document |
| December 04, 2007 Filed Dec 5, 2007 17:21 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 300 | $24.74 | $7,422.00 |
DisclosureSEC source: 0000875320-07-000118 · edgar.xml · nonDerivative · entry 6 BOGER JOSHUA S · CIK 0001197023 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,095,842 F1 · kind: Transaction for sales of common stock made pursuant to Dr. Boger's company approved trading plan established under Rule 10b5-1. F6 · kind: Aggregate sales made at prices between $24.72 and $24.77. Read SEC document |
| December 04, 2007 Filed Dec 5, 2007 17:21 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 2,700 | $24.84 | $67,068.00 |
DisclosureSEC source: 0000875320-07-000118 · edgar.xml · nonDerivative · entry 5 BOGER JOSHUA S · CIK 0001197023 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,096,142 F1 · kind: Transaction for sales of common stock made pursuant to Dr. Boger's company approved trading plan established under Rule 10b5-1. F5 · kind: Aggregate sales made at prices between $24.80 and $24.89. Read SEC document |
| December 04, 2007 Filed Dec 5, 2007 17:21 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 5,700 | $24.96 | $142,272.00 |
DisclosureSEC source: 0000875320-07-000118 · edgar.xml · nonDerivative · entry 4 BOGER JOSHUA S · CIK 0001197023 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,098,842 F1 · kind: Transaction for sales of common stock made pursuant to Dr. Boger's company approved trading plan established under Rule 10b5-1. F4 · kind: Aggregate sales made at prices between $24.90 and $24.99. Read SEC document |
| December 04, 2007 Filed Dec 5, 2007 17:21 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 7,600 | $25.04 | $190,304.00 |
DisclosureSEC source: 0000875320-07-000118 · edgar.xml · nonDerivative · entry 3 BOGER JOSHUA S · CIK 0001197023 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,104,542 F1 · kind: Transaction for sales of common stock made pursuant to Dr. Boger's company approved trading plan established under Rule 10b5-1. F3 · kind: Aggregate sales made at prices between $25.00 and $25.09. Read SEC document |
| December 04, 2007 Filed Dec 5, 2007 17:21 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,200 | $25.16 | $30,192.00 |
DisclosureSEC source: 0000875320-07-000118 · edgar.xml · nonDerivative · entry 2 BOGER JOSHUA S · CIK 0001197023 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,112,142 F1 · kind: Transaction for sales of common stock made pursuant to Dr. Boger's company approved trading plan established under Rule 10b5-1. F2 · kind: Aggregate sales made at prices between $25.10 and $25.20. Read SEC document |
| December 04, 2007 Filed Dec 5, 2007 17:21 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 17,500 | $13.67 | $239,225.00 |
DisclosureSEC source: 0000875320-07-000118 · edgar.xml · nonDerivative · entry 1 BOGER JOSHUA S · CIK 0001197023 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,113,342 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 29, 2007 Filed Nov 30, 2007 19:21 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option · Derivative | 17,500 | $0.00 Strike: $13.67 | $0.00 |
DisclosureSEC source: 0000875320-07-000117 · edgar.xml · derivative · entry 9 BOGER JOSHUA S · CIK 0001197023 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,686 Underlying: Common Stock · 17,500 shares Expires 2007-12-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: Fully vested. Read SEC document |
| November 29, 2007 Filed Nov 30, 2007 19:21 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 300 | $24.76 | $7,428.00 |
DisclosureSEC source: 0000875320-07-000117 · edgar.xml · nonDerivative · entry 6 BOGER JOSHUA S · CIK 0001197023 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,095,842 F1 · kind: Transaction for sales of common stock made pursuant to Dr. Boger's company approved trading plan established under Rule 10b5-1. F6 · kind: Aggregate sales made at prices between $24.75 and $24.79. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.